AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
21 Aug 2018 07:00 AM
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2018 07:00 AM
RNS
EMA grants OD for selumetinib in NF1
01 Aug 2018 03:00 PM
RNS
Total Voting Rights
27 Jul 2018 02:00 PM
RNS
CHMP recommends Imfinzi for Stage III nsclc
26 Jul 2018 07:00 AM
RNS
AZN: H1 2018 Results
24 Jul 2018 07:00 AM
RNS
Atacand to be divested to Cheplapharm in Europe
18 Jul 2018 12:00 PM
RNS
Holding(s) in Company
02 Jul 2018 03:00 PM
RNS
Total Voting Rights
02 Jul 2018 07:00 AM
RNS
Imfinzi approved in Japan for Stage III nsclc
02 Jul 2018 07:00 AM
RNS
Lynparza approved in Japan for BRCAm breast cancer
29 Jun 2018 03:00 PM
RNS
Bydureon receives positive CHMP opinion for BCise
28 Jun 2018 01:30 PM
RNS
AZ and Luye Pharma complete agreement for Seroquel
27 Jun 2018 07:00 AM
RNS
Lynparza: significant PFS 1st-line ovarian cancer
26 Jun 2018 07:00 AM
RNS
Board Committee Changes
22 Jun 2018 07:00 AM
RNS
Publication of a Prospectus
12 Jun 2018 07:00 AM
RNS
Update: lanabecestat Phase III Alzheimer's trials
08 Jun 2018 05:30 PM
RNS
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
08 Jun 2018 07:00 AM
RNS
Director Declaration
01 Jun 2018 03:00 PM
RNS
Block listing Interim Review
01 Jun 2018 03:00 PM
RNS
Total Voting Rights
01 Jun 2018 11:00 AM
RNS
Director Declaration
30 May 2018 07:00 AM
RNS
Update on TERRANOVA PIII trial for Fasenra in COPD
25 May 2018 07:00 AM
RNS
AZ's Imfinzi: significant OS in Stage III nsclc
21 May 2018 07:00 AM
RNS
AZ regulatory submission in Japan for Forxiga
21 May 2018 07:00 AM
RNS
US FDA approves Lokelma for adult hyperkalaemia
18 May 2018 05:30 PM
RNS
Result of AGM
18 May 2018 07:00 AM
RNS
AZN: Q1 2018 Results
11 May 2018 07:00 AM
RNS
AstraZeneca update on Fasenra PIII trial in COPD
08 May 2018 11:00 AM
RNS
EMA approves Lynparza: maintenance ovarian cancer
08 May 2018 07:00 AM
RNS
AZ and Luye Pharma enter agreement for Seroquel
04 May 2018 12:00 PM
RNS
Director Declaration
01 May 2018 03:00 PM
RNS
Total Voting Rights
27 Apr 2018 12:30 PM
RNS
AZ: positive CHMP for Tagrisso first-line nsclc
24 Apr 2018 07:00 AM
RNS
AstraZeneca:high level results of the ARCTIC trial
19 Apr 2018 07:00 AM
RNS
FDA approves Tagrisso for 1st-line use in NSCLC
13 Apr 2018 11:00 AM
RNS
Notice of AGM
05 Apr 2018 07:00 AM
RNS
Directorate Change
03 Apr 2018 03:00 PM
RNS
Total Voting Rights
03 Apr 2018 07:00 AM
RNS
FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
03 Apr 2018 07:00 AM
RNS
AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
28 Mar 2018 03:00 PM
RNS
Director/PDMR Shareholding
26 Mar 2018 03:00 PM
RNS
Director/PDMR Shareholding
22 Mar 2018 04:48 PM
RNS
Lokelma approved in the EU
12 Mar 2018 07:00 AM
RNS
ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
07 Mar 2018 07:00 AM
RNS
Filing of Form 20-F with SEC
06 Mar 2018 11:00 AM
RNS
Annual Financial Report
01 Mar 2018 03:00 PM
RNS
Total Voting Rights
23 Feb 2018 12:35 PM
RNS
Lynparza CHMP for ovarian cancer maintainance
19 Feb 2018 07:00 AM
RNS
AstraZeneca's IMFINZI approved for Stage III nsclc
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings